Hence, to build a progress in PCa therapy, it is essential to understand the detailed mechanisms accounting for anti-androgenic activity and resistance to AR antagonists and consequently to develop other strategies to overcome tumor growth progression. The gene discussed is AR; the disease is neoplasm.